The new site is for people in the U.S. who are willing to pay out of pocket for certain brand-name medications, like Zepbound ...
There's another fight brewing around GLP-1 drugs -- this time on the delivery side.
Novo Nordisk is facing "unprecedented" price pressures, "intensifying competition" and patents expiring.
MarketBeat on MSN
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months. In large part, that rebound was fueled ...
The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...
2don MSN
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...
With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results